The prevalence of obesity and type 2 diabetes is increasing worldwide and threatens to shorten lifespan. Impaired insulin action in peripheral tissues is a major pathogenic factor. Insulin stimulates glucose uptake in adipose tissue through the GLUT4 (also known as SLC2A4) glucose transporter, and alterations in adipose tissue GLUT4 expression or function regulate systemic insulin sensitivity. Downregulation of human and mouse adipose tissue GLUT4 occurs early in diabetes development. Here we report that adipose tissue GLUT4 regulates the expression of carbohydrateresponsive-element-binding protein (ChREBP; also known as MLXIPL), a transcriptional regulator of lipogenic and glycolytic genes. Furthermore, adipose ChREBP is a major determinant of adipose tissue fatty acid synthesis and systemic insulin sensitivity. We find a new mechanism for glucose regulation of ChREBP: glucose-mediated activation of the canonical ChREBP isoform (ChREBP-a) induces expression of a novel, potent isoform (ChREBP-b) that is transcribed from an alternative promoter. ChREBP-b expression in human adipose tissue predicts insulin sensitivity, indicating that it may be an effective target for treating diabetes.
Insulin resistance is a common complication of obesity and a major factor in the pathogenesis of type 2 diabetes and cardiovascular disease 1 . Adipose tissue contributes to the development of obesity-related insulin resistance through increased release of fatty acids, altered adipokine secretion, and/or macrophage infiltration and cytokine release 2, 3 . Altered adipose tissue glucose metabolism is also an important cause of insulin resistance, and adipose tissue GLUT4, the major insulinresponsive glucose transporter, has a central role in systemic glucose metabolism 1, 4, 5 . In insulin-resistant states, GLUT4 is downregulated in adipose tissue, but not in muscle 1 , the major site of insulin-stimulated glucose uptake. In addition, mice with adipose-specific GLUT4 overexpression (AG4OX) have improved glucose homeostasis 5 whereas adipose-specific GLUT4 knockout mice (AG4KO) have insulin resistance and type 2 diabetes 4 . We investigated how altering adipose tissue glucose flux regulates glucose homeostasis. We show that ChREBP, a glucose-responsive transcription factor that regulates fatty acid synthesis and glycolysis 6 , is highly regulated by GLUT4 in adipose tissue and is a key determinant of systemic insulin sensitivity and glucose homeostasis. Also, ChREBP in adipose tissue is required for the improved glucose homeostasis resulting from increased adipose GLUT4 expression. GLUT4-mediated glucose uptake induces ChREBP, which activates adipose tissue de novo lipogenesis (DNL). The latter is associated with enhanced insulin sensitivity [7] [8] [9] [10] . In obese humans, adipose ChREBP gene expression correlates with insulin sensitivity, suggesting that ChREBP protects against obesity-associated insulin resistance. In addition, we discovered a novel mechanism for glucose-regulated ChREBP expression involving a new isoform, ChREBP-b, which is expressed from an alternative promoter in a glucose-and ChREBP-dependent manner. In contrast, expression of the canonical ChREBP-a isoform is not regulated by glucose flux. However, glucose-induced ChREBP-a transcriptional activity increases ChREBP-b expression. Furthermore, expression of ChREBP-b is more highly regulated than ChREBP-a in adipose tissue in insulin-resistant states. Thus, activation of adipose ChREBP, and particularly ChREBP-b, may be a novel strategy for preventing and treating obesity-related metabolic dysfunction and type 2 diabetes ( Supplementary Fig. 1 ).
Glucose regulates adipose tissue ChREBP
To understand the mechanisms by which adipocytes respond to changes in glucose flux, we analysed global gene expression in adipose tissue from AG4OX and AG4KO mice. Gene-set enrichment analysis 11 demonstrated coordinate upregulation of DNL enzymes in AG4OX mice ( Supplementary Table 1 ), which we confirmed ( Fig. 1a ). DNL enzymes were downregulated in AG4KO mice ( Fig. 1a ). Therefore we investigated the expression of the two major transcription factors known to regulate DNL enzymes, sterol regulatory-element-bindingprotein 1c (SREBP-1c; also known as isoform 1c of SREBF1) and ChREBP 6,12 . ChREBP, but not SREBP-1c, expression is increased 50% in AG4OX and decreased 44% in AG4KO adipose tissue compared to controls ( Fig. 1b ). SREBP-1c transcriptional activity is primarily determined by the accumulation of mature SREBP-1c in the nucleus 13 . However, the nuclear abundance of SREBP-1c is not increased in AG4OX adipose tissue ( Supplementary Fig. 2a ). Liver X receptors (LXR-a and LXR-b; also known as NR1H3 and NR1H2, respectively) can regulate the expression of both ChREBP and SREBP-1c 14, 15 , and DNL enzymes 16 . Expression of canonical LXR targets do not change ( Supplementary Fig. 2b ) in AG4OX or AG4KO adipose tissue, indicating that LXR activity is unaffected and is not driving the changes in ChREBP or DNL enzyme expression. In contrast, expression of Rgs16 and Txnip, two ChREBP transcriptional targets [17] [18] [19] not known to be regulated by other lipogenic transcription factors, were reciprocally regulated in AG4OX and AG4KO mice ( Supplementary Fig. 2c ). In AG4KO and control mice (Fig. 1c ), and also in 30 different mouse strains ( Supplementary Fig. 3 ), adipose ChREBP expression strongly correlates with GLUT4 expression. Expression of ChREBP transcriptional targets FAS (also known as Fasn) and Acc1 (also known as Acaca) also strongly correlates with ChREBP expression across these strains ( Supplementary Fig. 3 ). Thus, adipose ChREBP may mediate the effects of altered GLUT4 expression and glucose flux on lipogenic enzyme expression.
ChREBP mediates effects of adipose GLUT4
Increased DNL in adipose tissue is associated with enhanced glucose tolerance and insulin sensitivity 20, 21 . Consistent with the increases in ChREBP and DNL enzyme expression ( Fig. 1a, b ), DNL in vivo is increased in perigonadal and subcutaneous white adipose tissue (WAT) in AG4OX mice compared to wild type ( Fig. 2a ).
To determine whether adipose ChREBP is required for the increased adipose tissue DNL resulting from GLUT4 overexpression, we crossbred AG4OX mice with whole-body ChREBP KO mice 6 . DNL normalizes in adipose tissue after deletion of ChREBP in AG4OX mice ( Fig. 2a ). Glucose incorporation into newly synthesized fatty acids is also decreased in wild-type and AG4OX adipose tissue after ChREBP knockout ( Supplementary Fig. 4 ). In liver, DNL is normal in AG4OX and AG4OX/ChREBP KO mice and is not decreased in ChREBP KO mice ( Fig. 2a ) contrasting with a prior report 6 . This difference may be attributable to differences in age, sex, genetic background and/or diet.
In parallel with a reduction in DNL in AG4OX adipose tissue after ChREBP deletion, DNL enzyme messenger RNA and protein expression levels also normalize ( Fig. 2b and Supplementary Fig. 5 ). Thus, ChREBP is a major regulator of DNL enzymes in adipose tissue and mediates the changes in DNL enzyme expression resulting from increased glucose flux.
AG4OX mice are obese ( Fig. 2c, d ) but have enhanced glucose tolerance ( Fig. 2e ) 5 . Increased body weight ( Fig. 2c ), adiposity ( Fig. 2d ) and a tendency towards increased food intake normalize with ChREBP deletion; energy expenditure was normal ( Supplementary  Fig. 6 ). In spite of obesity, AG4OX mice are more insulin sensitive than wild-type mice (Supplementary Table 2 ). Decreased fed glycaemia (Supplementary Table 2 ), markedly enhanced glucose tolerance ( Fig. 2e ), and lower glycaemia during insulin tolerance testing ( Fig. 2f ) in AG4OX mice normalized after ChREBP deletion. Genetically ablating ChREBP in wild-type and AG4OX mice impairs insulin sensitivity (Supplementary Table 2 ). ChREBP KO mice show modest glucose intolerance ( Fig. 2e ), as reported 6 . Glycaemia in ChREBP KO mice remains elevated after food removal compared to wild-type mice ( Fig. 2g ). ChREBP knockout prevents the hypoglycaemia that develops * * * 
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in AG4OX mice after food removal ( Fig. 2g ). ChREBP deletion did not decrease GLUT4 overexpression or glucose uptake ( Supplementary  Fig. 7 ) in AG4OX adipocytes, indicating that the mechanism by which ChREBP regulates glucose homeostasis is not by altering adipose tissue glucose uptake. The decreased insulin sensitivity and glucose tolerance in AG4OX/ChREBP KO mice is not due to elevated serum triglycerides or non-esterified fatty acids, as both metabolites decrease compared to AG4OX mice (Supplementary Table 2 ). The effects of ChREBP KO on metabolism and gene expression in AG4OX mice is likely to result from the absence of ChREBP specifically in adipose tissue, because ChREBP expression is increased in adipose tissue ( Fig. 1b) but not in liver of AG4OX mice ( Supplementary Fig. 8 ). Reversal of enhanced glucose tolerance and insulin sensitivity with normalization of DNL is consistent with a role for adipose tissue DNL in improving systemic glucose metabolism.
Obesity regulates adipose tissue ChREBP
High-fat diet (HFD) causes obesity and insulin resistance and downregulates GLUT4 expression selectively in adipose tissue 1 . To investigate whether adipose ChREBP expression has a role in the insulin resistance resulting from adipose GLUT4 downregulation, we subjected mice to HFD. On chow, AG4OX mice are obese (Figs 2c, d and 3a). AG4OX mice do not gain more weight on HFD and their degree of obesity on both diets is similar to HFD-fed wild-type mice ( Fig. 3a and Supplementary Fig. 9 ). HFD induces insulin resistance in both genotypes ( Supplementary Table 3 ). In wild-type mice, HFD causes a diabetic glucose tolerance test ( Fig. 3b ) but not in AG4OX mice. The enhanced glucose tolerance in AG4OX mice does not result from changes in serum metabolites typically associated with insulin sensitivity. AG4OX mice have higher non-esterified fatty acids and triglycerides, and lower leptin levels on both diets (Supplementary Table 3 ), and lower adiponectin levels 22 on chow compared to wild type. This pattern is thought to contribute to insulin resistance 2,3,23 and not to enhanced insulin sensitivity. HFD reduces expression of adipose tissue DNL enzymes 24, 25 which correlates with insulin resistance [7] [8] [9] [10] . Therefore, we examined whether downregulation of adipose ChREBP and DNL contributes to HFDinduced insulin resistance. HFD in wild-type mice reduces DNL in subcutaneous but not perigonadal adipose tissue, (Fig. 3c ). In AG4OX, HFD markedly reduces DNL in WAT, but DNL remains 2-7-fold higher than in wild-type mice on HFD. This intermediate rate of DNL parallels the change in glucose tolerance in AG4OX mice on HFD (Fig. 3b ). Changes in glucose incorporation into newly synthesized fatty acids ( Supplementary Fig. 10 ) are similar to the changes in total (from all substrates) DNL (Fig. 3c ) in WAT. In liver, DNL is not higher in AG4OX on either diet (Fig. 3c ). HFD inhibits adipose DNL independently of adipose tissue glucose uptake in AG4OX mice, as GLUT4 protein levels ( Supplementary Fig. 11 ) and glucose transport remain elevated 26 .
To investigate the mechanisms underlying HFD-induced changes in adipose DNL, we examined the expression of lipogenic transcription factors and DNL enzymes. In wild type mice, HFD diminishes ChREBP but not SREBP-1c expression in WAT (Fig. 3d) , as reported 25, 27 . In AG4OX WAT, HFD markedly decreases ChREBP and also SREBP-1c expression but ChREBP remains elevated compared to wild-type mice on HFD. Nevertheless, HFD reduces the degree of ChREBP induction in AG4OX adipose tissue despite persistent GLUT4 overexpression ( Supplementary Fig. 11 ). Thus, HFD may regulate ChREBP expression in part independently of GLUT4 expression and glucose flux, consistent with HFD effects on DNL (Fig. 3c) .
Many DNL enzymes that are upregulated in WAT of AG4OX on chow are downregulated in HFD-fed wild-type and AG4OX mice a * * * * ARTICLE RESEARCH ( Fig. 3e and Supplementary Fig. 12 ) but remain higher in AG4OX WAT compared to wild type in a pattern paralleling ChREBP expression ( Fig. 3d ) and DNL (Fig. 3c ). In wild-type WAT, ChREBP downregulation probably accounts for HFD-induced downregulation of DNL gene expression, as WAT SREBP-1c expression is not altered. Furthermore, whole-body genetic ablation of SREBP-1c does not diminish expression of these genes in WAT 28 . In contrast, both ChREBP and SREBP-1c expression are downregulated in WAT in AG4OX mice on HFD compared to chow (Fig. 3d ). Persistent modest elevation of ChREBP in WAT of AG4OX on HFD compared to wild type on HFD (Fig. 3d) is probably responsible for the increased DNL that contributes to improved glucose tolerance in AG4OX mice (Fig. 3b) . Unlike in wild-type WAT, in liver, HFD does not downregulate ChREBP and DNL enzyme expression ( Supplementary Fig. 13 ).
LXRs are unlikely to contribute to downregulation of ChREBP expression, DNL, or DNL enzyme expression in wild-type mice on HFD, because expression of LXRs and canonical LXR targets are either unchanged or modestly increased ( Supplementary Fig. 14) . MAX-like protein X (Mlx) is an obligate dimerization partner for ChREBP transcriptional activity 29 . Neither HFD nor GLUT4 overexpression alters MLX expression in WAT ( Supplementary Fig. 14) .
We next sought to determine whether adipose ChREBP might contribute to regulating insulin sensitivity and glucose homeostasis in humans. In 123 non-diabetic individuals with normal glucose tolerance and widely ranging body mass index (BMI) values ( Supplementary  Table 4 ), ChREBP expression in subcutaneous WAT correlates strongly with insulin sensitivity measured during a euglycaemic and hyperinsulinaemic clamp procedure (Fig. 3f ). Adipose tissue ChREBP correlates with GLUT4 ( Fig. 3g) , consistent with a role for ChREBP in the beneficial effects of adipose tissue GLUT4 expression on glucose homeostasis.
Most, but not all, obese people are insulin resistant. To determine whether adipose ChREBP expression could have a role in regulating insulin sensitivity in obese people, we also investigated adipose ChREBP expression in non-diabetic obese individuals with widely ranging insulin sensitivity ( Supplementary Table 4 ). Adipose ChREBP expression was directly associated with insulin-stimulated glucose uptake during a clamp, independent of BMI ( Fig. 3h) . Surprisingly, ChREBP and GLUT4 expression did not correlate in these obese individuals (Fig. 3i) . Thus, adipose ChREBP expression may have beneficial effects on insulin sensitivity, even among obese subjects, and this can be independent of GLUT4 expression.
Identification of a novel ChREBP isoform
The mechanism by which glucose activates ChREBP transcriptional activity is complex and controversial. It has been attributed to xylulose-5-phosphate-induced dephosphorylation of specific ChREBP residues 30 . Alternatively, glucose or a metabolite may prevent the interaction of an amino-terminal inhibitory domain with a glucose-activating domain within the ChREBP protein 31 . Glucose and other carbohydrates can also induce ChREBP expression 27 but whether this contributes to ChREBP activity is unknown. The mechanism for carbohydratemediated ChREBP induction may involve 'feed-forward' autoregulation, because a dominant-negative MLX mutant that inhibits ChREBP activity reduces endogenous ChREBP expression 19, 32 .
To investigate the molecular mechanisms by which ChREBP might transactivate its own expression, we searched the genomic sequence around the ChREBP transcriptional start site for a carbohydrate response element (ChoRE), which is defined by two E-boxes (CACGTG) separated by five nucleotides 33 . We identified a single candidate ChoRE 17 kb upstream of the mouse ChREBP transcriptional start site ( Supplementary Figs 15 and 16 ). Additionally, a separate E-box was identified 255 base pairs proximal to the putative ChoRE (Supplementary Fig. 16 ). In this region, the genomic sequence including the ChoRE and 59 E-box is highly conserved ( Supplementary Figs 16 and 17 ). H3K4me3 and H3K4me1 histone methylation marks aligned with this conserved genomic region ( Supplementary Fig. 18 ), suggesting the presence of an alternative promoter 34 and potentially an alternative first exon. By 59 rapid amplification of cDNA ends, we confirmed an 
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alternative first exon, exon 1b ( Fig. 4a and Supplementary Figs 16-18) , and cloned an mRNA species transcribed from this alternative promoter in which exon 1b is spliced to exon 2, bypassing exon 1a and retaining the remainder of exons present in the canonical ChREBP mRNA species (Fig. 4a ).
Physiological regulation of ChREBP isoforms
To determine whether the two distinct ChREBP mRNA species are physiologically regulated, we performed quantitative polymerase chain reaction (qPCR) with primers specific for exon 1a (ChREBP-a) or exon 1b (ChREBP-b). In WAT, ChREBP-a expression declines modestly with overnight fasting, and increases 64% after 3 h of re-feeding a chow diet compared to mice fed ad libitum (Fig. 4b) . In contrast, adipose ChREBP-b declines 45% after an overnight fast and increases 4.3-fold with re-feeding compared to ad libitum feeding. Thus, ChREBP-b expression is more highly regulated in WAT than ChREBP-a with fasting and re-feeding. In liver, ChREBP-a expression declines 40% and ChREBP-b expression tends to decline (25%) with overnight fasting. After 3 h of re-feeding, ChREBP-a remains suppressed whereas ChREBP-b returns to baseline. After 6 h of re-feeding, liver ChREBP-a levels return to normal (data not shown). Thus, in liver, the time course of ChREBP-a and ChREBP-b regulation differ.
To determine whether alterations in glucose flux selectively regulate ChREBP-a or ChREBP-b, we examined the expression of the two isoforms in AG4OX and AG4KO WAT. Total ChREBP expression increases 50% in AG4OX and decreases 50% in AG4KO WAT (Fig. 4d) . Adipose ChREBP-a expression remains unchanged in AG4OX and declines modestly in AG4KO. In contrast, in WAT, ChREBP-b increases 4.6-fold in AG4OX mice, and decreases 97% in AG4KO (Fig. 4c ). Considering the difference in magnitude of change of total ChREBP compared to ChREBP-b, ChREBP-b is probably much less abundant than ChREBP-a. Although expression of both ChREBP-a and ChREBP-b are nutritionally regulated (Fig. 4b) , ChREBP-b alone responds robustly to GLUT4-mediated changes in glucose flux (Fig. 4c ).
Glucose-activated ChREBP-a induces ChREBP-b
We investigated the molecular mechanism by which ChREBP-b expression is regulated in response to changes in adipose GLUT4 expression. Expression of a ChREBP-b-promoter-luciferase construct is markedly increased in a glucose-dependent manner with co-transfection of ChREBP-a and MLX (Fig. 4d) . MLX, the dimerization partner for ChREBP, is required for ChREBP transcriptional activity 29 . Co-transfection of both ChREBP-a and MLX was required for induction of ChREBP-b-promoter-luciferase activity in high glucose conditions ( Supplementary Fig. 19 ), indicating that ChREBP-b requires transactivation by ChREBP-a for expression. Basal and glucose-stimulated expression is attenuated with deletion of either the ChoRE or the upstream E-box and abolished entirely with deletion of both ( Fig. 4d ). Glucose and ChREBP-a/MLX had no effect on the expression of a luciferase reporter containing 5 kb of the ChREBP-a promoter, indicating that ChREBP-a does not regulate its own expression (data not shown). Thus, ChREBP-a specifically regulates expression of ChREBP-b.
The translational start site for ChREBP-a resides in exon 1a and translation from this site produces an 864-amino-acid protein. No translational start site is present in exon 1b and translation beginning at the next start site, in exon 4, produces a 687-amino-acid protein in which two nuclear export signals, a nuclear localization signal, and a domain that inhibits ChREBP transcriptional activity in low-glucose conditions are deleted ( Supplementary Fig. 20) 31, 35 . N-terminally deleted ChREBP mutants demonstrate increased nuclear localization and enhanced transcriptional activity in both low-and high-glucose conditions 31 . Using an ACC1-ChoRE-luciferase reporter construct 36 , we compared the transcriptional activity of ChREBP-a and ChREBP-b (Fig. 4e) . High glucose increased ChREBP-a transcriptional activity 2.4-fold over low glucose. ChREBP-b activity in either low or high glucose is increased ,20-fold compared to ChREBP-a activity in high glucose, and shows no glucose regulation. The elevated ChREBP-b transcriptional activity may result in part from absence of the N-terminal inhibitory domain or its constitutive nuclear localization in low-and high-glucose conditions ( Supplementary Fig. 21) . These results suggest a feed-forward mechanism in which glucose-stimulated ChREBP-a transactivates expression of ChREBP-b ( Fig. 4d and Supplementary Fig. 21 ), a more potent activator of ChREBP transcriptional targets (Fig. 4e ).
Pathophysiological regulation of ChREBP-a/b
In mice fed a HFD, ChREBP-b expression declines in WAT whereas ChREBP-a expression remains unchanged (Fig. 5a) , consistent with the possibility that downregulation of adipose ChREBP-b contributes to insulin resistance.
In human WAT, expression of both ChREBP-a and ChREBP-b correlate with insulin sensitivity (Fig. 5b) . Multiple linear regression analysis demonstrates that expression of ChREBP-b (b 5 0.454, P 5 0.016) and not ChREBP-a (b 5 0.136, P 5 0.356) predicts insulin sensitivity ( Supplementary Table 5 ).
Implications
Adipocytes are key regulators of whole-body energy homeostasis and metabolic function 2, 4 . Our prior work demonstrating that adipose GLUT4 expression regulates systemic insulin sensitivity 4, 5 indicated that adipocytes are capable of sensing and coordinating responses to changes in glucose availability. The elucidation here of the molecular mechanism by which glucose-mediated ChREBP activation transactivates expression of a novel, potent ChREBP-b ( Supplementary Fig. 22 ) isoform reveals the complexity underlying cellular responses to nutrient availability. Our data demonstrate that adipose tissue ChREBP has a key role in integrating adipocyte and whole-body metabolic function and this may be mediated by transcriptional regulation of the potent ChREBP-b isoform.
The beneficial effects of adipose tissue ChREBP on glucose homeostasis may result from upregulation of adipose tissue DNL and/or other ChREBP-dependent actions such as changing the metabolic fate of glucose after it enters adipocytes and/or regulating a novel adipokine. The strong, direct correlation between adipose ChREBP expression and insulin sensitivity in humans suggests that adipose ChREBP may be involved in regulating whole-body insulin action. The beneficial metabolic effects of increased DNL in adipose tissue contrast with the adverse effects in the liver. DNL in liver increases intrahepatic triglyceride content and may contribute to insulin resistance and the metabolic syndrome 37, 38 . In summary, our data support the importance of adipose ChREBP in regulating insulin 
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action and glucose homeostasis in human obesity and diabetes. These data suggest that selective activation of adipose tissue ChREBP, and specifically ChREBP-b, could be an effective therapeutic strategy for preventing and treating type 2 diabetes and obesity-related metabolic diseases.
METHODS SUMMARY
AG4OX, AG4KO and ChREBP KO mice were described previously [4] [5] [6] except that AG4KO mice were generated using adiponectin-Cre-expressing mice 39 rather than aP2-Cre-expressing mice for all studies except for DNA microarrays. Phenotypic analyses were performed as described 4, 5, 40 . All mouse studies were conducted in accordance with federal guidelines and were approved by the BIDMC Institutional Animal Care and Use Committee. For microarray analysis, RNA was isolated from perigonadal adipose tissue and the cDNA was analysed on the Affymetrix MG-U74-A.v2 Genechip. Quantitative real-time PCR was performed on the Applied Biosystems 7900 HT using SYBR Green PCR Master Mix. Cloning, mutagenesis, and luciferase assays were performed by standard methods. Human subjects were recruited as described 37, 41 . Human studies were approved by the Human Studies Committee of Washington University School of Medicine or the Ethics Committee of the University of Leipzig.
